aTyr Pharma (NASDAQ:LIFE) is scheduled to be announcing its earnings results on Wednesday, March 14th.
aTyr Pharma (NASDAQ LIFE) opened at $3.00 on Tuesday. aTyr Pharma has a 12-month low of $2.30 and a 12-month high of $6.50. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.49 and a current ratio of 9.49. The firm has a market capitalization of $89.28, a PE ratio of -1.48 and a beta of 3.54.
A number of research analysts have recently weighed in on the company. Zacks Investment Research cut aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. cut aTyr Pharma from a “neutral” rating to an “underweight” rating in a research report on Wednesday, February 14th. Finally, ValuEngine cut aTyr Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. aTyr Pharma presently has an average rating of “Hold” and a consensus target price of $4.56.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.